Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 8/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19552312 | 0.84 | FFAR1 (0.53) | FFAR1LPLLIPGF11DGAT1 | |
| SCHEMBL31030386 | 0.84 | FFAR1 (0.56) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL15334053 | 0.83 | FFAR1 (0.49) | FFAR1IRAK4 | |
| SCHEMBL15359061 | 0.83 | FFAR1 (0.49) | FFAR1IRAK4 | |
| SCHEMBL15377247 | 0.83 | FFAR1 (0.49) | FFAR1IRAK4 | |
| SCHEMBL1559915 | 0.82 | FFAR1 (0.57) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL15376095 | 0.81 | FFAR1 (0.50) | FFAR1CNR1CNR2 | |
| SCHEMBL15377147 | 0.81 | FFAR1 (0.50) | FFAR1CNR1CNR2 | |
| SCHEMBL2513372 | 0.81 | FFAR1 (0.50) | FFAR1CNR1CNR2 | |
| SCHEMBL18985768 | 0.81 | FFAR1 (0.56) | FFAR1LPLLIPGF11IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4236932-B1 | DEGRADANT COMPOUND IN A MEDICAMENT | VISUS THERAPEUTICS INC (US) | 2026-01-07 | — | — | EP | claimed |
| EP-3946183-B1 | A FLOW CONTROL DEVICE FOR DELIVERING AN OPHTHALMIC FORMULATION | TEARCLEAR CORP (US) | 2025-10-29 | — | — | EP | claimed |
| EP-3270892-B1 | FIXED DOSE COMBINATION OF BRIMONIDINE AND TIMOLOL | ALLERGAN INC (US) | 2024-04-10 | — | — | EP | claimed |
| EP-3179982-B1 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | SUN PHARMA ADVANCED RES CO LTD (IN) | 2023-07-19 | — | — | EP | claimed |
| US-20230072164-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | ALTERNO LABS D.O.O. (SI) | 2023-03-09 | — | — | US | disclosed |
| EP-4096642-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | Alterno Labs d.o.o. (SI) | 2022-12-07 | — | — | EP | disclosed |
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| EP-3013832-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| EP-2714677-B1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-9273029-B2 | Pyridine-and pyrazine derivatives | MERCK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-8455484-B2 | Selected inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-06-04 | — | — | US | disclosed |
| WO-2012161877-A1 | PYRIDINE-AND PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2011127567-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011127565-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND USE THEREOF TO TREAT OPHTHALMIC DISORDERS | METHYLGENE INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257175-A1 | Selected Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | FFAR1 86/4885IKBKE 2394/4885TBK1 909/4885 |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | FFAR1 86/4885IKBKE 2394/4885TBK1 909/4885 |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | FFAR1 2744/4885IKBKE 231/4885TBK1 179/4885 |
| US-20110257175-A1 | Selected Inhibitors of Protein Tyrosine Kinase Activity | ABL1, PRKDC, PRKACA | FFAR1 3849/4885IKBKE 345/4885TBK1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.